Efficacy and Safety of Intracameral Bevacizumab for Treatment of Neovascular Glaucoma

• 발행기관: 대한안과학회
• 저자명: Jun Young Ha Tae Hee Lee Mi Sun Sung Sang Woo Park
• 간행물 정보: 『The Korean Journal of Ophthalmology』Vol.31 No.6, 538~547쪽, 전체 10쪽
• 주제분류: 인문학 > 역사학
• 파일형태: PDF
• 발행일자: 2017.12.30

영문 초록

Purpose: To evaluate the long-term efficacy and safety of intracameral bevacizumab in patients with neovascular glaucoma. Methods: This retrospective study included 26 eyes of 26 neovascular glaucoma patients who received intracameral bevacizumab injection between January 2013 and May 2015, and were followed-up for at least 1 year. All patients were treated with topical and/or systemic intraocular pressure (IOP)-lowering medications, intracameral bevacizumab, and panretinal photocoagulation (PRP). The main outcome measures were changes in visual acuity, IOP, and neovascularization of the iris (NVI) and the anterior chamber angle (NVA). To assess the safety of intracameral bevacizumab, corneal endothelial changes were also determined using specular microscopy. Patients whose IOP was uncontrolled received IOP-lowering surgery. Clinical factors associated with IOP-lowering surgery were also investigated. Results: In all patients, intracameral bevacizumab resulted in a rapid and marked reduction of IOP, NVI, and NVA within 1 week. At 12 months after initial injection, 19 of 26 eyes (73%) underwent IOP-lowering surgery. The average interval between initial injection and surgical treatment was 33.6 ± 26.9 days. Baseline IOP(p = 0.018), NVA grade (p = 0.029), and incomplete PRP (p = 0.005) were identified as predictive factors for IOP-lowering surgery. During the follow-up period, there were no statistically significant corneal endothelial changes after intracameral bevacizumab injection. Conclusions: During 1 year of follow-up after intracameral bevacizumab, the procedure was found to be safe for the corneal endothelium. However, the IOP-lowering effect was transient, and 73% of patients eventually required IOP-lowering surgery. Predictive factors for IOP-lowering surgery were high baseline IOP and NVA grade, and incomplete PRP.

목차

Materials and Methods

Results

Discussion

Conflict of Interest

References

키워드

Bevacizumab Intracameral injection Neovascular glaucoma Vascular endothelial growth factor